中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

104 records (took 0.024 seconds)

    HABER-BOSCH CATALYST COMPRISING AN ANION-VACANT LATTICE
    12.
    发明申请
    HABER-BOSCH CATALYST COMPRISING AN ANION-VACANT LATTICE 有权

    公开(公告)号：US20210114005A1

    公开(公告)日：2021-04-22

    申请号：US17050313

    申请日：2019-04-24

    Applicant: THE UNIVERSITY OF WARWICK

    Inventor： Shanwen Tao ,  John Humphreys

    IPC: B01J27/24 ,  B01J23/755 ,  B01J23/745 ,  B01J23/10 ,  B01J23/78 ,  C01C1/04

    Abstract: A composition for catalysis of a Haber-Bosch process comprises an anion vacant lattice and a Haber-Bosch catalyst (e.g. Fe Ru). Suitable anion vacant lattices include oxynitrides and oxides, which may be doped or undoped, including CeaMbO2-XNY (Formula III) M is one or more elements with a valence lower than +4. “a” and “b” are independently in the range 0.05 to 0.95, with the proviso that “a” and “b” together sum to 1 (approximately). X is greater than 0 and less than 2. Y is greater than zero and less than or equal to X. A process employing the composition produces ammonia.

    CHARGE CARRIER MULTIPLIER STRUCTURE
    14.
    发明申请
    CHARGE CARRIER MULTIPLIER STRUCTURE 审中-公开

    公开(公告)号：US20200173845A1

    公开(公告)日：2020-06-04

    申请号：US16303726

    申请日：2017-05-22

    Applicant: The University of Warwick

    Inventor： Gavin BELL ,  Yorck Ramachers ,  Raffaello DA CAMPO

    IPC: G01J1/42 ,  H01J40/16 ,  G01N21/33 ,  G01N21/25

    Abstract: A charge carrier multiplier structure for a light sensor, in particular an ultraviolet light sensor, is described. The charge carrier multiplier structure comprises a dielectric sheet having first and second opposite faces and having an array of holes traversing the dielectric sheet between the first and second faces, at least two photocathodes supported on the first face of the dielectric sheet that are electrically isolated from each other and which define at least two sensing regions, each photocathode having a respective work function and quantum yield and having a respective area and at least one anode supported on the second face of the dielectric sheet.

    ANTIMICROBIAL AGENTS
    15.
    发明申请
    ANTIMICROBIAL AGENTS 审中-公开

    公开(公告)号：US20200048183A1

    公开(公告)日：2020-02-13

    申请号：US16606845

    申请日：2018-04-23

    Applicant: THE UNIVERSITY OF WARWICK

    Inventor： Gregory Leonard CHALLIS ,  Xinyun JIAN ,  Christian HOBSON ,  Joleen Solange Liesbet MASSCHELEIN

    IPC: C07C69/757 ,  C07D309/10 ,  C07C271/12

    Abstract: The invention provides novel analogues of enacyloxin Ha and their pharmaceutically acceptable salts, metabolites, isomers (e.g. stereoisomers) and prodrugs. Such compounds are effective in the treatment of infections caused by Gram-negative bacteria such as Acinetobacter baumannii. Compounds in accordance with the invention include those of formula (A), and their pharmaceutically acceptable salts, metabolites, isomers (e.g. stereoisomers) and prodrugs: In formula (A): X is 0 or NRx (where R* is either H or C1-3 alkyl, e.g. CH3); R1 is a 5- or 6-membered, saturated or unsaturated, carbocyclic ring optionally substituted by one or more substituents, or R1 is an optionally substituted straight-chained or branched C1-6 alkyl group (e.g. C1-3 alkyl group); R2 is H, F, Cl, Br, I or CH3; R3 is H or OH; R8 is a straight-chained or branched C1-8 alkyl group (e.g. a C1-6 alkyl group); Y is one of the following groups: (wherein each * denotes the point of attachment of the group to the remainder of the molecule; R9 is H, F, Cl, Br or I; R4 and R5 are independently selected from H and OH, or R4 and R5 together are =0, preferably R4 is H and R5 is OH; R6 is H, F, Cl, Br, I or CH3; R7 is H and R7′ is OH, or R7 and R7′ together are =0, preferably R7 is H and R7′ is OH); and each — independently represents an optional bond (i.e. each of C2-C3, C4-C5, C6-C7, C8-C9 and C10-C11 are independently either C—C (single) or C═C (double) bonds).

    ANTIMICROBIAL AGENTS
    17.
    发明申请
    ANTIMICROBIAL AGENTS 审中-公开

    公开(公告)号：US20190127313A1

    公开(公告)日：2019-05-02

    申请号：US16094617

    申请日：2017-04-21

    Applicant: THE UNIVERSITY OF WARWICK

    Inventor： Gregory Leonard CHALLIS ,  Daniel John GRIFFITHS ,  Joleen Solange Liesbet MASSCHELEIN

    IPC: C07C69/732 ,  C12P7/64 ,  C07C69/738 ,  C07C235/28 ,  A61K31/232 ,  C12P13/02

    Abstract: The invention provides novel compounds of formula (I) and their pharmaceutically acceptable salts, metabolites, isomers (e.g. stereoisomers) and prodrugs. Such compounds are effective in the treatment of infections caused by Gram-negative bacteria such as Acinetobacter baumannii. In formula (I), X is O, NR (where R is either H or C1-3 alkyl, e.g. CH3), or CH2; R3 is H, F, CI, Br, I, or CH3; R4 is H, or OH; R5 and R6 are independently selected from H and OH, or R5 and R6 together are ═O; R7 is H, F, CI, Br, I, or CH3; R8 is H, OH, or —OC(O)NR′2 (where each R′ is independently H or C1-3 alkyl, e.g. CH3), preferably R8 is H, OH or —OC(O)NH2; R9 is a 5- or 6-membered, saturated or unsaturated, carbocyclic ring optionally substituted by one or more substituents, or R9 is an optionally substituted straight-chained or branched C1-6 alkyl group (e.g. C1-3 alkyl group); R10 is a straight-chained or branched C1-8 alkyl group (e.g. C1-6 alkyl group), a C4-6 cycloalkyl group, or an optionally substituted aryl or heteroaryl group; and each --- independently represents an optional bond (i.e. each of C2-C3, C4-C5, C6-C7, C8-C9, C10-C11 and C18-C19 are independently either C—C (single) or C═C (double) bonds).

    PREIMPLANTATION SCREENING
    18.
    发明申请
    PREIMPLANTATION SCREENING 审中-公开

    公开(公告)号：US20190032106A1

    公开(公告)日：2019-01-31

    申请号：US15775223

    申请日：2016-11-11

    Applicant: University of Warwick

    Inventor： Scarlett SALTER ,  Jan BROSENS

    IPC: C12Q1/37 ,  G01N33/68

    Abstract: The present invention relates to a method of assessing the viability of an embryo, wherein the method comprises a step of: measuring the level and/or activity of a protein marker selected from either TMPRSS2 or PRSS8 in a sample of culture medium, wherein the sample has been obtained from the in vitro culture medium of an embryo produced by in vitro fertilization, wherein the level and/or activity of the protein marker is indicative of the viability of the embryo.

Patent Agency Ranking